Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients

Inclusion Criteria: * Type I or II diabetes patients aged 18 to 75 years (including 18 and 75 years), regardless of gender; * Stable peritoneal dialysis patients who have undergone peritoneal dialysis treatment for ≥ 3 months; * Use 3-5 bags of peritoneal dialysis solution daily; * 6.0%\<glycated hemoglobin (HbA1c) level ≤ 8.5%; * 90g/L ≤ Hemoglobin concentration ≤ 130g/L * Stable use of erythropoietin and rosuvastatin; * The fluctuation of carbohydrate energy supply ratio in the first 3 months before enrollment is less than 15%; * Not using amino acid (15) peritoneal dialysis solution for the first 3 months before enrollment; * Within the past month, the patient's prescription for hypoglycemic drugs has not been adjusted; * Within the past month, the patient's dietary structure and food intake have remained stable. Exclusion Criteria: * Peritonitis has occurred within the past 3 months; * Use Acodextrin peritoneal dialysis solution; * Contraindications for the presence of amino acids (15) in peritoneal dialysis fluid: 1. Individuals allergic to any component of amino acid (15) peritoneal dialysis fluid; 2. Serum urea level\>38 mmol/l; 3. Metabolic acidosis (CO2 binding capacity\<22mmol/L); 4. Severe hypokalemia (blood potassium\<2.5mmol/L); 5. Various congenital amino acid metabolism abnormalities; 6. Liver dysfunction (alanine aminotransferase levels exceeding 2.5 times the upper limit of normal); * Combined hemoglobinopathies: such as thalassemia, sickle cell disease, etc; * It is expected that kidney transplantation may be accepted during the trial period; * Participated in other clinical studies.